Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade B 17.77 -6.82% -1.30
ARWR closed down 6.82 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ARWR trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Outside Day Range Expansion 0.00%
Mar 21 Crossed Above 20 DMA Bullish -6.82%
Mar 21 Bollinger Band Squeeze Range Contraction -6.82%
Mar 20 20 DMA Resistance Bearish -4.15%
Mar 20 Bollinger Band Squeeze Range Contraction -4.15%
Mar 19 20 DMA Resistance Bearish -5.63%
Mar 19 Bollinger Band Squeeze Range Contraction -5.63%
Mar 19 Inside Day Range Contraction -5.63%

Older signals for ARWR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Biology Organ Systems Solid Tumors Infection Molecular Biology Genetics Obesity Gene Expression Hepatitis B RNA Molecular Genetics Apoptosis Chronic Hepatitis B Virus
Is ARWR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.39
52 Week Low 6.26
Average Volume 1,657,961
200-Day Moving Average 15.1641
50-Day Moving Average 16.6766
20-Day Moving Average 18.9815
10-Day Moving Average 18.794
Average True Range 0.8697
ADX 21.93
+DI 20.9366
-DI 20.6557
Chandelier Exit (Long, 3 ATRs ) 17.9909
Chandelier Exit (Short, 3 ATRs ) 20.1791
Upper Bollinger Band 20.224
Lower Bollinger Band 17.739
Percent B (%b) 0.01
BandWidth 13.091695
MACD Line 0.4485
MACD Signal Line 0.7056
MACD Histogram -0.2571
Fundamentals Value
Market Cap 1.33 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -27.77
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.99
Resistance 3 (R3) 20.24 19.74 19.62
Resistance 2 (R2) 19.74 19.18 19.62 19.50
Resistance 1 (R1) 18.76 18.83 18.51 18.51 19.37
Pivot Point 18.26 18.26 18.14 18.14 18.26
Support 1 (S1) 17.28 17.70 17.03 17.03 16.17
Support 2 (S2) 16.78 17.35 16.66 16.04
Support 3 (S3) 15.80 16.78 15.92
Support 4 (S4) 15.55